AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:13 13/02/2026 GMT			5-day change	1st Jan Change
15,118.00 ^GBX	+1.42%		+7.19%	+9.63%

02-13	Sector Update: Health Care Stocks Advance Late Afternoon	MT
02-13	Sector Update: Health Care Stocks Higher Friday Afternoon	MT

ASTRAZENECA : Deutsche Bank gives a Sell rating

Published on 01/16/2026 at 10:36 am GMT

MarketScreener with dpa-AFX Analyser

ASTRAZENECA PLC

+1.42%

Deutsche Bank reiterate its Sell rating. The target price is reviewed upwards from GBX 10500 to GBX 11000.

Latest news about AstraZeneca PLC

02-13	Sector Update: Health Care Stocks Advance Late Afternoon	MT
02-13	Sector Update: Health Care Stocks Higher Friday Afternoon	MT
02-13	European Equities Mixed in Friday Trading; Spain's January CPI Declines	MT
02-13	AstraZeneca Announces Positive and clinically meaningful Results from the Phase III KALOS and Logos Trials for Breztri in Patients with Undundant Ast Astrazeneca's Breztri in Patients	CI
02-13	Shore Capital Downgrades AstraZeneca to Hold Rating	MT
02-13	Stocks edge lower ahead of US CPI data	AN
02-13	Stockholm Stock Exchange Declines on Friday After Intense Earnings Week	FW
02-13	ASTRAZENECA : Bernstein maintains a Buy rating	ZD
02-13	Bernstein, Barclays and Deutsche lower Relx	AN
02-13	China Medical University Hospital Collaborates with Ever Supreme Bio Technology to Develop Exosome Platform	CI
02-13	AstraZeneca rises on positive trial results for asthma therapy	AN
02-13	AstraZeneca Says Breztri Improves Lung Function, Reduces Attacks in Phase 3 Asthma Trials	MT
02-13	NatWest results ahead of forecasts, ups dividend 51%	AN
02-13	Swedish Stocks in North America - Ericsson Up 0.9 Percent	FW
02-12	AbbVie sues US health agency over Botox price controls	RE

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (5.8%). Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).

Employees

94,300

Sector

Pharmaceuticals

Calendar

03-09 - Leerink Global Healthcare Conference

More about the company